synTEG

SynTEG therapeutics is developing synTEG-01, an autologous engineered T-cell therapy that targets a metabolic dysregulation induced antigen complex on cancer cells across multiple tumor types. Its engineered receptor combination—a γ9δ2 TCR plus an anti‑BTN3A chimeric costimulatory receptor—has been designed to enable potent tumor killing, enhanced T‑cell fitness, and longer persistence of engineered T cells than conventional CAR‑T approaches. Previously, engineered T cells expressing the γ9δ2 TCR, called TEG001, have been assessed in a phase I clinical trial and the concept has been licensed to Gadeta B.V. (later acquired by Clade Tx.). SynTEG Therapeutics improved the concept by the addition of an anti‑BTN3A chimeric costimulatory receptor, for which patent applications are currently in the national phase.  The preclinical in vitro and in vivo data of synTEG-01 shows deep remission in both liquid and solid tumor models, prolonged survival, and durable protection after tumor rechallenge, supporting the product’s potential to overcome key limitations of current engineered T-cell therapies such as T cell exhaustion and relapse.

SynTEG-01 will be clinically validated in relapsed/refractory acute myeloid leukemia (rrAML)—a high-unmet-need indication affecting a growing patient population, with approximately 45,000 AML cases annually in the US and EU and 50–70% of patients relapsing or becoming refractory to current treatments. The AML market is projected to grow from USD 3.91B in 2025 to USD 9.79B by 2034, supporting a significant commercial opportunity for differentiated therapies. Based on reactivity data of synTEG-01 predecessor, TEG001, it is estimated that leukemic cells of ~50% of rrAML patients can be targeted by synTEG-01, representing 8,000–12,500 eligible patients annually in the US and EU.

The founding team synTEG consist of the inventors Dr. Dennis Beringer (CEO) and Prof. Jürgen Kuball M.D (CSO/CMO and former CSO Gadeta B.V.), alongside Dr. Trudy Straetemans (CTO-CMC Lead synTEG-01) and Dr. Zsolt Sebestyén (CTO-CMC lead Gene delivery), who have built strong institutional CMC infrastructure at UMC Utrecht, that successfully delivered TEG001 into a Phase I trial and bring regulatory approval experience for CAR-T clinical development. The team is further supported by Dr. Valentina Vignali a venture partner of Utrecht Holdings Seed Fund.